Zhao Hong-Jie, Guo Li-Ping, Yang Feng-Wen, Zhang Ming-Yan, Zhang Li-Shuag, Liu Zhi, Li Yue, Ji Zhao-Chen, Zhang Jun-Hua, Zheng Wen-Ke
Center for Evidence-based Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193,China.
Baokang Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193,China.
Zhongguo Zhong Yao Za Zhi. 2017 Apr;42(8):1495-1499. doi: 10.19540/j.cnki.cjcmm.2017.0047.
This systematic review aims to evaluate the efficacy and safety of Huoxiang Zhengqi formulas in treating gastrointestinal type cold. Seven electronic databases,including CNKI, WanFang Data, Vip, SinoMed, PubMed, Cochrane Library, Embase will be searched from the inception of the study until March 2017.All randomized controlled trials that evaluate the treatment of Huoxiang Zhengqi formulas for gastrointestinal type cold will be eligible. The methodological quality will be assessed using the Cochrane risk of bias tool for randomized clinical trials and Review Manager 5.3 software is used for analyzing the data.The results are： eight RCTs and 680 patients are included .Meta-analysis are performed according to the stratification of the treatment strategy. Eight studies report clinical efficacy, among them four studies show Huoxiang Zhengqi formulas are better than western medicine(RR and 95%,1.2[1.08, 1.33]), another four studies showHuoxiang Zhengqi formulas in conjunction with conventional treatment are better than conventional treatment(RR and 95%, 1.32[1.20,1.46]).About symptom remission rate, one study shows the treatment group effect is better than the control group from the following clinical symptoms：chills,fever,bowel diarrhea,the effect of treating sore throat itchy is same with western medicine treatment.No adverse reactions are found about Huoxiang Zhengqi formulas in this study.Current evidence shows that Huoxiangzhengqi formulas are better than Western medicine group and western medicine routine treatment group from clinical efficacy. Limited by the quantity and quality of studies, more large-scale and rigorously designed randomised controlled trials with large sample size are warranted to clarify the conclusions.
本系统评价旨在评估藿香正气制剂治疗胃肠型感冒的疗效和安全性。检索7个电子数据库，包括中国知网、万方数据、维普、中国生物医学文献数据库、PubMed、考克兰图书馆、Embase，检索时间从研究开始至2017年3月。所有评估藿香正气制剂治疗胃肠型感冒的随机对照试验均符合纳入标准。采用考克兰偏倚风险工具对随机临床试验的方法学质量进行评估，并使用Review Manager 5.3软件进行数据分析。结果显示：纳入8项随机对照试验，共680例患者。根据治疗策略分层进行Meta分析。8项研究报告了临床疗效，其中4项研究显示藿香正气制剂优于西药（相对危险度及95%可信区间，1.2[1.08, 1.33]），另外4项研究显示藿香正气制剂联合常规治疗优于常规治疗（相对危险度及95%可信区间，1.32[1.20,1.46]）。关于症状缓解率，1项研究显示治疗组在以下临床症状方面的效果优于对照组：畏寒、发热、腹泻，治疗咽喉瘙痒的效果与西药治疗相同。本研究未发现藿香正气制剂有不良反应。目前的证据表明，藿香正气制剂在临床疗效方面优于西药组和西药常规治疗组。受研究数量和质量的限制，需要更多大规模、设计严谨、样本量充足的随机对照试验来明确结论。
